EGFR Positive Lung Cancer Latest Advances

Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.

Journal: Annals of medicine

Published: October 15, 2025

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 06, 2025

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Journal: Cureus

Published: September 13, 2025

Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

Journal: Journal of medicinal chemistry

Published: September 09, 2025

Radiogenomics-based prediction of KRAS and EGFR gene mutation in non-small cell lung cancer patients.

Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Published: September 08, 2025

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

Journal: Future oncology (London, England)

Published: August 22, 2025

Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: August 21, 2025

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Journal: Bioorganic & medicinal chemistry

Published: August 19, 2025

Dual Blockade of PI3K and EGFR Pathways by Flavonoids from Idesia polycarpa Maxim Cake Meal: Valorization of Agro-Industrial Waste for NSCLC Therapy.

Journal: Foods (Basel, Switzerland)

Published: August 13, 2025

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Journal: Internal medicine (Tokyo, Japan)

Published: August 13, 2025

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Journal: Internal medicine (Tokyo, Japan)

Published: August 13, 2025

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.

Journal: bioRxiv : the preprint server for biology

Published: August 13, 2025

Filters

Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.

Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

Radiogenomics-based prediction of KRAS and EGFR gene mutation in non-small cell lung cancer patients.

Radiogenomics-based prediction of KRAS and EGFR gene mutation in non-small cell lung cancer patients.

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.

Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)

Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Dual Blockade of PI3K and EGFR Pathways by Flavonoids from Idesia polycarpa Maxim Cake Meal: Valorization of Agro-Industrial Waste for NSCLC Therapy.

Dual Blockade of PI3K and EGFR Pathways by Flavonoids from Idesia polycarpa Maxim Cake Meal: Valorization of Agro-Industrial Waste for NSCLC Therapy.

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Response to "The Afatinib Response to EGFR E709G-mutated Lung Cancer".

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.